1. Academic Validation
  2. Structure-Based Virtual Screening Identifies 2-Arylthiazole-4-Carboxylic Acids as a Novel Class of Nanomolar Affinity Ligands for the CaMKIIα Hub Domain

Structure-Based Virtual Screening Identifies 2-Arylthiazole-4-Carboxylic Acids as a Novel Class of Nanomolar Affinity Ligands for the CaMKIIα Hub Domain

  • J Med Chem. 2025 Feb 13;68(3):3031-3047. doi: 10.1021/acs.jmedchem.4c02265.
Yongsong Tian 1 Vasileios Fougiaxis 1 Ludovica Stella Sirocchi 1 Stine Juul Gauger 1 Anne Sofie Gry Larsen 1 Elena Martino 1 Camilla Bachmand Chan 1 Christoffer Bundgaard 2 Sara M Ø Solbak 1 Petrine Wellendorph 1 Mohamed A Shehata 1 Bente Frølund 1
Affiliations

Affiliations

  • 1 Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen, Denmark.
  • 2 Translational DMPK, H. Lundbeck A/S, Ottiliavej 9, DK-2500 Valby, Denmark.
Abstract

The CA2+/calmodulin-dependent protein kinase II α (CaMKIIα) plays a crucial role in regulating Neuronal Signaling and higher brain functions, being involved in various brain diseases. Utilization of small molecules targeting the CaMKIIα hub domain has proved to be a promising strategy for specific CaMKIIα modulation and future therapy. Through an in silico structure-based virtual screening campaign, we herein identified 2-arylthiazole-4-carboxylic acids as a new class of high-affinity CaMKIIα hub ligands. Particularly, the 2,6-dichlorophenyl analog, PTCA (compound 1a), displayed mid-nanomolar affinity (pKi = 7.2) and substantial stabilization of the CaMKIIα hub oligomer upon binding. Moreover, the tert-butyl ester prodrug, 14a, was developed to facilitate the brain delivery of PTCA and demonstrated remarkable enhancement in brain penetration compared to PTCA per se after systemic administration. Altogether, our study highlights that PTCA represents a novel and powerful tool compound for future pharmacological interventions targeting CaMKII kinase in the brain.

Figures
Products